Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer

BACKGROUND: The immunohistochemical (IHC) 4+C score is a cost-effective prognostic tool that uses clinicopathologic factors and four standard IHC assays: oestrogen receptor (ER), PR, HER2 and Ki67. We assessed its utility in personalising breast cancer treatment in a clinical practice setting, throu...

Descripción completa

Detalles Bibliográficos
Autores principales: Barton, S, Zabaglo, L, A'Hern, R, Turner, N, Ferguson, T, O'Neill, S, Hills, M, Smith, I, Dowsett, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364112/
https://www.ncbi.nlm.nih.gov/pubmed/22531639
http://dx.doi.org/10.1038/bjc.2012.166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364112/
https://www.ncbi.nlm.nih.gov/pubmed/22531639
http://dx.doi.org/10.1038/bjc.2012.166

Ejemplares similares